Company intelligence / Profile preview
Sevapharma
Czechiasevapharma.cz ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Sevapharma specializes in the production of immunological preparations and reagents for immunochemical and biochemical diagnostics. Its lead product, Trivivac, is an approved live attenuated combination vaccine targeting rubella infections. The company’s products are used for both prophylactic vaccination and diagnostic purposes[1][2].
- Therapeutic areas
- Infectious Diseases
- Modalities
- Live attenuated vaccineCombination vaccineProphylactic vaccine
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Biogenetech Co. Ltd. (Trivivac active organization/distributor in Thailand)[2]
Beyond the preview
Go deeper on Sevapharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sevapharma.